Suppr超能文献

序贯抗心律失常治疗对慢性非瓣膜性心房颤动患者成功电复律后窦性心律维持的疗效

Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation.

作者信息

Kosior D, Opolski G, Torbicki A

机构信息

Department of Internal Diseases and Cardiology, 1st Faculty of Medicine, Medical University in Warsaw, ul. Banacha 1a, 02-097 Warsaw, Poland.

出版信息

Med Sci Monit. 2001 Jan-Feb;7(1):68-73.

Abstract

BACKGROUND

Sequential use of antiarrhythmic drugs may improve prognosis in chronic atrial fibrillation (AF). We conducted a prospective study of the efficacy of sequential antiarrhythmic drug therapy in sinus rhythm (SR) maintenance after a successful electrocardioversion (CV) in pts with chronic AF.

MATERIAL AND METHODS

58 pts (64.3 +/- 4.3 years old) with chronic AF underwent CV. After SR restoration (Group I) pts received one of the following antiarrhythmic drugs (Drug I): propafenone, sotalol or disopyramide. In case of arrhythmia recurrence, second CV was performed and pts received another drug from those mentioned above (Drug II). If treatment proved to be unsuccessful pts received amiodarone (Drug III) and third CV was attempted. After first unsuccessful CV (Group II) pts received a loading dose of amiodarone and another CV was attempted. In case of SR restoration amiodarone was administered continuously.

RESULTS

After 12 months 81% pts were on SR; 85% pts received amiodarone continuously. After 1 year 6 (10%) pts presented with SR treated with Drug I (median 71 days); Drug II proved to be ineffective in all patients (median 27 days). 28 pts continued to receive amiodarone (no median).

CONCLUSIONS

Sequential antiarrhythmic drug therapy improves arrhythmia prognosis in AF within a 12-month observation period. Amiodarone seems to be the most effective antiarrhythmic drug also in pts who required second CV proceeded by amiodarone treatment to restore SR.

摘要

背景

序贯使用抗心律失常药物可能改善慢性房颤(AF)的预后。我们进行了一项前瞻性研究,以评估序贯抗心律失常药物治疗对慢性房颤患者成功电复律(CV)后维持窦性心律(SR)的疗效。

材料与方法

58例(64.3±4.3岁)慢性房颤患者接受了电复律。恢复窦性心律后(I组),患者接受以下抗心律失常药物之一(药物I):普罗帕酮、索他洛尔或丙吡胺。若心律失常复发,则进行第二次电复律,患者接受上述另一种药物(药物II)。若治疗失败,患者接受胺碘酮(药物III)并尝试进行第三次电复律。首次电复律失败后(II组),患者接受胺碘酮负荷剂量并再次尝试电复律。若恢复窦性心律,则持续给予胺碘酮。

结果

12个月后,81%的患者维持窦性心律;85%的患者持续接受胺碘酮治疗。1年后,6例(10%)患者使用药物I维持窦性心律(中位数71天);药物II对所有患者均无效(中位数27天)。28例患者继续接受胺碘酮治疗(无中位数)。

结论

在12个月的观察期内,序贯抗心律失常药物治疗可改善房颤患者的心律失常预后。对于那些需要在胺碘酮治疗后进行第二次电复律以恢复窦性心律的患者,胺碘酮似乎也是最有效的抗心律失常药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验